跳至主要内容
临床试验/ISRCTN71305621
ISRCTN71305621已完成未知

Optimising Individualised prescribing with therapeutic drug Monitoring for Antipsychotics (OptIMA) 2: Clinical pilot study of antipsychotic drug level monitoring - a pilot multicentre open-label single-arm clinical trial

Institute of Psychiatry, Kings College London (UK)0 个研究点目标入组 32 人开始时间: 2010年11月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
32

研究概览

简要总结

2015 results in https://pubmed.ncbi.nlm.nih.gov/26040903/ (added 07/08/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged 18 - 65 years, either sex
  • 2. Schizophrenia/schizoaffective disorder (clinician International Classification of Disease [ICD-10] diagnosis)
  • 3. Symptoms of acute psychosis
  • 4. Admitted in past two weeks to participating inpatient acute wards
  • 5. Routine clinician initiation (including switch/new initiation/recommencement) of regularly daily prescribed olanzapine as antipsychotic monotherapy, i.e., only one daily antipsychotic drug
  • 6. Legally detained participants will be permitted if they have capacity to consent to the study

排除标准

  • 1. Use of clozapine in past 12 months (i.e. whose illness has been classified as 'treatment resistant') but who are now prescribed olanzapine. This is because they would not be expected to benefit from changes in olanzapine dosage.
  • 2. Use of another simultaneous regularly prescribed daily antipsychotic (other than p.r.n) at study onset

研究者

发起方
Institute of Psychiatry, Kings College London (UK)

相似试验